Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people
Kurt Taylor,Sophie Eastwood,Venexia Walker,Genevieve Cezard,Rochelle Knight,Marwa Al Arab,Yinghui Wei,Elsie M F Horne,Lucy Teece,Harriet Forbes,Alex Walker,Louis Fisher,Jon Massey,Lisa E M Hopcroft,Tom Palmer,Jose Cuitun Coronado,Samantha Ip,Simon Davy,Iain Dillingham,Caroline Morton,Felix Greaves,John Macleod,Ben Goldacre,Angela Wood,Nishi Chaturvedi,Jonathan A C Sterne,Rachel Denholm,Longitudinal Health and Wellbeing and Data and Connectivity UK COVID-19 National Core Studies,CONVALESCENCE study,OpenSAFELY collaborative,Fatima Almaghrabi,Colm Andrews,Ellena Badrick,Sarah Baz,Chelsea Beckford,Samantha Berman,Tom Bolton,Charlotte Booth,Ruth Bowyer,Andy Boyd,Charis Bridger-Staatz,Sinead Brophy,Archie Campbell,Kirsteen C Campbell,Alisia Carnemolla,Jd Carpentieri,Nathan Cheetham,Ruth Costello,Thomas Cowling,Matthew Crane,Jose Ignacio Cuitun Coronado,Helen Curtis,Spiros Denaxas,Giorgio Di Gessa,Richard Dobson,Ian Douglas,Katharine M Evans,Chao Fang,Vanessa Ferreira,Lucy Finnigan,Robin Flaig,Amos Folarin,Diane Foster,Laura Fox,Maxim Freydin,Paz Garcia,Andy Gibson,Fiona Glen,Ana Goncalves Soares,Amelia Green,Mark Green,Michael Green,Gareth Griffith,Lee Hamill Howes,Olivia Hamilton,Annie Herbet,Emily Herrett,Lisa Hopcroft,Elsie Horne,Bo Hou,Alun Hughes,William Hulme,Lizzie Huntley,Wels Jacques,Peter Jezzard,Louise Jones,Arun Kanagaratnam,Arun Karthikeyan Suseeladevi,Vittal Katikireddi,John Kellas,Jonathan I Kennedy,Milla Kibble,Anika Knueppel,Daniel Kopasker,Theocharis Kromydas,Alex Kwong,Sinead Langan,Agnieszka Lemanska,Elena Lukaschuk,Brain Mackenna,Jane Maddock,Viyaasan Mahalingasivam,Kathryn Mansfield,Fintan McArdle,Daniel McCartney,Rosie McEachan,Eoin McElroy,Stela McLachlan,Ruth Mitchell,Bettina Moltrecht,Jess Morley,Linda Nab,Stefan Neubauer,Lidia Nigrelli,Teri North,Kate Northstone,Jacqui Oakley,Chloe Park,Michael Parker,Sam Parsons,Praveetha Patalay,Kishan Patel,Francisco Perez-Reche,Stefan Piechnik,Dominik Piehlmaier,George Ploubidis,Elena Rafeti,Betty Raman,Yatharth Ranjan,Alicja Rapala,Rebecca Rhead,Amy Roberts,Alexia Sampri,Zeena-Britt Sanders,Gillian Santorelli,Laura C Saunders,Anoop Shah,Syed Ahmar Shah,Steve Sharp,Richard Shaw,Laura Sheard,Aziz Sheikh,Richard Silverwood,Liam Smeeth,Stephen Smith,Jean Stafford,Andrew Steptoe,Jonathan Sterne,Claire Steves,Callum Stewart,John Tazare,Richard Thomas,Ellen Thompson,Kate Tilling,Nicholas Timpson,Laurie Tomlinson,Renin Toms,Elizabeth Tunnicliffe,Emma L Turner,Scott Walter,Kevin Wang,Rebecca Whitehorn,Bozena Wielgoszewska,James M Wild,Kathryn Willan,Robert Willans,Dylan Williams,Andrew Wong,Hannah Woodward,John Wright,Tiffany Yang,Paola Zaninotto,Bang Zheng,Jingmin Zhu
DOI: https://doi.org/10.1016/S2213-8587(24)00159-1
Abstract:Background: Some studies have shown that the incidence of type 2 diabetes increases after a diagnosis of COVID-19, although the evidence is not conclusive. However, the effects of the COVID-19 vaccine on this association, or the effect on other diabetes subtypes, are not clear. We aimed to investigate the association between COVID-19 and incidence of type 2, type 1, gestational and non-specific diabetes, and the effect of COVID- 19 vaccination, up to 52 weeks after diagnosis. Methods: In this retrospective cohort study, we investigated the diagnoses of incident diabetes following COVID-19 diagnosis in England in a pre-vaccination, vaccinated, and unvaccinated cohort using linked electronic health records. People alive and aged between 18 years and 110 years, registered with a general practitioner for at least 6 months before baseline, and with available data for sex, region, and area deprivation were included. Those with a previous COVID-19 diagnosis were excluded. We estimated adjusted hazard ratios (aHRs) comparing diabetes incidence after COVID-19 diagnosis with diabetes incidence before or in the absence of COVID-19 up to 102 weeks after diagnosis. Results were stratified by COVID-19 severity (categorised as hospitalised or non-hospitalised) and diabetes type. Findings: 16 669 943 people were included in the pre-vaccination cohort (Jan 1, 2020-Dec 14, 2021), 12 279 669 in the vaccinated cohort, and 3 076 953 in the unvaccinated cohort (both June 1-Dec 14, 2021). In the pre-vaccination cohort, aHRs for the incidence of type 2 diabetes after COVID-19 (compared with before or in the absence of diagnosis) declined from 4·30 (95% CI 4·06-4·55) in weeks 1-4 to 1·24 (1·14-1.35) in weeks 53-102. aHRs were higher in unvaccinated people (8·76 [7·49-10·25]) than in vaccinated people (1·66 [1·50-1·84]) in weeks 1-4 and in patients hospitalised with COVID-19 (pre-vaccination cohort 28·3 [26·2-30·5]) in weeks 1-4 declining to 2·04 [1·72-2·42] in weeks 53-102) than in those who were not hospitalised (1·95 [1·78-2·13] in weeks 1-4 declining to 1·11 [1·01-1·22] in weeks 53-102). Type 2 diabetes persisted for 4 months after COVID-19 in around 60% of those diagnosed. Patterns were similar for type 1 diabetes, although excess incidence did not persist beyond 1 year after a COVID-19 diagnosis. Interpretation: Elevated incidence of type 2 diabetes after COVID-19 is greater, and persists for longer, in people who were hospitalised with COVID-19 than in those who were not, and is markedly less apparent in people who have been vaccinated against COVID-19. Testing for type 2 diabetes after severe COVID-19 and the promotion of vaccination are important tools in addressing this public health problem. Funding: UK National Institute for Health and Care Research, UK Research and Innovation (UKRI) Medical Research Council, UKRI Engineering and Physical Sciences Research Council, Health Data Research UK, Diabetes UK, British Heart Foundation, and the Stroke Association.